Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.